X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
The trial is expected to provide further clinical proof-of-concept of Kiadis’ K-NK003 product.
Lead Product(s): K-NK cells,Cytarabine,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: K-NK003
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
RDD 2024
Not Confirmed
Contact SupplierDetails:
A poster presentation demonstrates results of multiple FC21-NK infusions in R/R AML patients with CNS disease, treated in an investigator-initiated Phase I/II study.
Lead Product(s): Interleukin-21-Expanded Haploidentical NK Cells,Cytarabine,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
RDD 2024
Not Confirmed
Contact SupplierDetails:
The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).
Lead Product(s): Natural killer cells,Filgrastim,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
RDD 2024
Not Confirmed
Contact Supplier
Details:
Under the agreement, Kincell will manufacture Imugene’s Azer-cel (azercabtagene zapreleucel), an off-the-shelf (allogeneic) cell therapy CAR T drug, to support ongoing clinical trials.
Lead Product(s): Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Imugene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 16, 2024
Details:
NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy, which is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma.
Lead Product(s): NY-ESO-1 TCR/IL-15,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: NY-ESO-1 TCR/IL-15
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syena
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
CB-012 is an allogeneic anti-CLL-1 CAR-T cell therapy that exhibits specific and potent cytotoxicity. It is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia.
Lead Product(s): CB-012,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: CB-012
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
IDP-023 is an allogeneic G-NK cell therapy, which is being evaluated for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.
Lead Product(s): IDP-023,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: IDP-023
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 1 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Lead Product(s): Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KO-539
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
PTCy (post-transplant cyclophosphamide) in combination with Busulfan, Fludarabine & Tacrolimus is being evaluated for the treatment of patients with blood cancers who have received peripheral blood stem cells from partially matched unrelated donors.
Lead Product(s): Cyclophosphamide,Busulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: PTCy
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The net proceeds will be used for the development of KYV-101 for the patients suffering from autoimmune diseases such as multiple sclerosis and myasthenia gravis.
Lead Product(s): KYV-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $366.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 12, 2024
Details:
The net proceeds will be used for the development of KYV-101 for the patients suffering from autoimmune diseases such as multiple sclerosis and myasthenia gravis.
Lead Product(s): KYV-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $319.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2024
Details:
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, which is being evaluated in phase 1/2 clinical trials for the treatment of idiopathic inflammatory myopathies (IIM, or myositis).
Lead Product(s): CABA-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Musculoskeletal Product Name: CABA-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
The net proceeds will be used for the clinical development of ADI-001 for the treatment of autoimmune diseases and relapsed or refractory aggressive B-cell NHL with a current focus on mantle cell lymphoma patients.
Lead Product(s): ADI-001,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $98.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 25, 2024
Details:
Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel, a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer.
Lead Product(s): Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MaxCyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2024
Details:
AUTO1 (obecabtagene autoleucel) is a CD19 CAR T cell investigational therapy. It is being evaluated in phase 1/2 clinical trials for the treatment of relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia.
Lead Product(s): Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AUTO1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
IDP-023 is a natural killer (NK) cell therapy which is currently being investigated in phase 1/2 clinical studies for the treatment of multiple myeloma and Non-Hodgkin’s lymphoma.
Lead Product(s): IDP-023,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: IDP-023
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
AB-201 is a novel CAR-NK cell therapy targeting solid tumors, represents a breakthrough in cancer immunotherapy, capable of killing malignant cells. It is being evaluated in phase 1/2 clinical studies for the treatment of HER2-overexpressing breast cancer.
Lead Product(s): AB-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AB-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
ALLO-501A (cemacabtagene ansegedleucel) isbeing evaluated in clinical studies for the treatment of patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL).
Lead Product(s): Cemacabtagene Ansegedleucel,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-501A
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
OBX-115 is a cell and gene therapy drug candidate, which is being evaluated in combination with for the treatment of patients with advanced or metastatic melanoma.
Lead Product(s): OBX-115,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: OBX-115
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
The collaboration aims to evaluate Kura’s menin inhibitor, KO-539 (ziftomenib), in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.
Lead Product(s): Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride
Therapeutic Area: Oncology Product Name: KO-539
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leukemia & Lymphoma Society
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2023
Details:
NXC-201 (formerly HBI0101) is an IND approved, BCMA-targeted investigational CAR-T cell therapy that is being studied in patients with relapsed/refractory AL amyloidosis.
Lead Product(s): NXC-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Genetic Disease Product Name: NXC-201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells. It is indicated for treating relapsed/refractory large B-cell lymphoma.
Lead Product(s): Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Yescarta
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
BEAM-201 is a quadruplex base-edited, anti-CD7 allogeneic chimeric antigen receptor T cell (CAR-T) under clinical investigation for the treatment of CD7+ relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL).
Lead Product(s): BEAM-201,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: BEAM-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
Imugene gains global rights to PBCAR0191 (azercabtagene zapreleucel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing trial for azer-cel in the large B-cell lymphoma and has an option to develop up to three other cancer research programs.
Lead Product(s): Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Imugene
Deal Size: $662.0 million Upfront Cash: $29.0 million
Deal Type: Licensing Agreement August 15, 2023
Details:
IVS-3001 is Invectys’ cutting-edge CAR-T cell therapy, targeting the rarely exploited immune checkpoint and tumor specific antigen known as HLA-G, which is investigated for the treatment of Renal Cell Carcinoma.
Lead Product(s): IVS-3001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
PBCAR0191 (azercabtagene zapreleucel) is an investigational anti-CD19 allogeneic CAR T candidate being evaluated in a Phase 1/2a clinical trial of adult subjects with relapsed or refractory (R/R) non-Hodgkin lymphoma.
Lead Product(s): Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
IVS-3001 is Invectys’ cutting-edge CAR-T cell therapy, targeting the rarely exploited immune checkpoint and tumor specific antigen known as HLA-G, which is investigated for the treatment of Solid Tumors.
Lead Product(s): IVS-3001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: M.D. Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
The proceeds will fund manufacturing and clinical development of company's CB-010 and CB-011 product candidates; IND-enabling activities, manufacturing, and clinical development of its CB-012 product candidate and preclinical development of its CB-020 product candidate.
Lead Product(s): CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: CB-010
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 13, 2023
Details:
LN-145 TIL therapy for patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced (unresectable or metastatic) NSCLC without EGFR, ROS or ALK genomic mutations
Lead Product(s): LN-145,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells and is being investigated for Relapsed or Refractory Acute Myeloid Leukemia.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma.
Lead Product(s): ADI-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.
Lead Product(s): TT11X,Nivolumab,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: TT11X
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2023
Details:
The funds will be used to progress the company's pipeline of enhanced cell therapies for solid tumors and hematologic cancers, including ACE1831 and ACE2016. ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy for patients with non-Hodgkin Lymphoma.
Lead Product(s): Allogenic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1831
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Digital Mobile Venture
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 06, 2023
Details:
The Proceeds will support the clinical development of MT-101, Myeloid’s lead cell therapy program in Phase 1/2 for T cell lymphoma, and will accelerate the development of MT-302, a first-in-class TROP2-FcA mRNA-LNP product, into a Phase 1/2 for TROP2-expressing tumors.
Lead Product(s): MT-101,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: MT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hatteras Investment Partners
Deal Size: $73.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 18, 2023
Details:
Anti-GD2 CAR NKT-Cell Therapy targeting BTG1 which is identified as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. It is being developed for relapsed/refractory neuroblastoma.
Lead Product(s): GINAKIT Cell Therapy,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Baylor College of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
The collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies including, TAK-007, a CD19 chimeric antigen receptor-directed cord blood derived natural killer cell therapy.
Lead Product(s): TAK-007,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: TAK-007
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 12, 2023
Details:
Under the agreement, Precigen regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform. Precigen will utilize the UltraCAR-T platform for unencumbered development and commercialization of two proven CAR-T targets, CD19 and BCMA.
Lead Product(s): Autologous CAR-T Cell-based Therapy,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PRGN-3007
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Precigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 03, 2023
Details:
PRGN-3007 is the next generation of UltraCAR-T incorporating PD-1 inhibition, it simultaneously express a chimeric antigen receptor (CAR) targeting ROR1, mbIL15, a kill switch, and a novel mechanism for the intrinsic blockade of PD-1 gene. expression.
Lead Product(s): PRGN-3007,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: PRGN-3007
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Gedeptin (Ad/PNP) is a gene-directed enzyme prodrug therapy (GDEPT) that results in the formation of the oncolytic agent within the tumor itself, resulting in tumor cell death while significantly limiting systemic exposure.
Lead Product(s): Ad/PNP,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Gedeptin
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
ALLO-316, an AlloCAR T investigational product targets CD70, which is highly expressed in RCC. CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors.
Lead Product(s): ALLO-316,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-316
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
ALLO-715 is an anti-BCMA (B-cell maturation antigen) AlloCAR T therapy product candidate which is being developed as a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
Lead Product(s): ALLO-715,ALLO-647,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ALLO-715
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T-lymphocyte product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology.
Lead Product(s): Gamma Delta T-lymphocyte,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
JSP191 (briquilimab) is a targeted, monoclonal antibody that inhibits the cell-surface receptor c-KIT, also known as CD117. It is currently being evaluated as a primary therapeutic for mast cell diseases.
Lead Product(s): Briquilimab,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: JSP191
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
Lomab-B (apamistamab-I-131) is a first-in-class targeted radiotherapy intended to improve patient access to potentially curative BMT by simultaneously and rapidly depleting blood cancer, immune and bone marrow stem cells that uniquely express CD45.
Lead Product(s): Apamistamab-I-131,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Iomab-B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
ITIL-306 is an autologous TIL cell therapy engineered with CoStAR molecule (activated by folate receptor alpha), which enhances the cytokine release, cytolytic activity, and proliferation of TILs in the tumor microenvironment.
Lead Product(s): ITIL-306,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ITIL-306
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
PBCAR0191 (azercabtagene zapreleucel) is an investigational anti-CD19 allogeneic CAR T candidate being evaluated in a Phase 1/2a clinical trial of adult subjects with relapsed or refractory (R/R) non-Hodgkin lymphoma.
Lead Product(s): Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
FT576 (CAR NK cells) is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line. FT576 incorporates a proprietary CAR that targets BCMA, a novel high-affinity 158V and non-cleavable CD16 (hnCD16) Fc receptor.
Lead Product(s): Allogenic CAR NK Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: FT576
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Janssen
Deal Size: $3,100.0 million Upfront Cash: $100.0 million
Deal Type: Termination January 05, 2023
Details:
CNCT19 (Inaticabtagene Autoleucel), is the first CAR-T cell therapy for the treatment of B-ALL submitted for NDA and has the potential to be the first approved domestic developed CD19 directed CAR-T therapy in China.
Lead Product(s): Inaticabtagene Autoleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CNCT19
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Alemtuzumab was added to the LD regimen to sustain host T-cell and Natural Killer (NK) cell depletion and to promote UCART22 cell expansion and persistence.
Lead Product(s): UCART22,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: UCART22
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
CB-010 is the lead product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 trial.
Lead Product(s): CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: CB-010
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
